NCT02902809View on ClinicalTrials.gov

A Study to Evaluate the Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma

PHASE3TerminatedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

November 11, 2016

Primary Completion Date

January 19, 2018

Study Completion Date

January 19, 2018

Conditions
Inadequately Controlled Asthma
Interventions
BIOLOGICAL

Tralokinumab open-label

Subcutaneous injection; fixed dose; 300 mg

Trial Locations (3)

103-0027

Research Site, Chūōku

173-8610

Research Site, Itabashi-ku

236-0004

Research Site, Yokohama

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY